Market Cap€66m

Last Close €2.56

TxCell is developing regulatory T-cell therapies against autoimmune and inflammatory disorders using a novel CAR Treg technology platform.It is a subsidiary of Sangamo.

More TxCell content >

Investment summary

TxCell has announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell. A further offer for the remaining shares is underway. Sangamo is a leading US biotech company and operates TxCell as a subsidiary. Sangamo intends to evaluate the potential of CAR-Treg therapies to prevent graft rejection in solid organ transplant and for the treatment of autoimmune diseases such as Crohn’s disease and multiple sclerosis, with trials from 2019. Sangamo intends to use its zinc finger nuclease gene-editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2016A 0.0 (11.9) (12.7) (97.5) N/A N/A
2017A 0.0 (9.3) (9.7) (46.3) N/A N/A
2018E 0.0 (11.8) (11.9) (53.0) N/A N/A
2019E 0.0 (11.9) (12.0) (53.7) N/A N/A
Content on TxCell
Executive interview – TxCell
Healthcare | Edison TV | 4 September 2018
TxCell – Getting production in order
Healthcare | research Update | 14 August 2018
TxCell – Humanised CAR Tregs are a key step forward
Healthcare | research Update | 14 August 2018
View more
Share price graph
Balance sheet
Forecast net debt (€m) 12.2
Forecast gearing ratio (%) 246
Price performance
Actual 1.0 9.7 55.8
Relative* 11.7 18.7 68.3
52-week high/low €2.6/€0.9
*% relative to local index
Key management
Stéphane Boissel CEO
Raphael Flipo CFO